Drug-resistant epilepsy drug Ontozry backed by NICE
pharmaphorum
NOVEMBER 16, 2021
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The post Drug-resistant epilepsy drug Ontozry backed by NICE appeared first on.
Let's personalize your content